AU Patent

AU2018351936A1 — Treatment of obesity-related conditions

Assigned to Instituto de Medicina Molecular Joao Lobo Antunes · Expires 2020-05-14 · 6y expired

What this patent protects

This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds for the inhibition of Slc6a2 outside the bra…

USPTO Abstract

This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds for the inhibition of Slc6a2 outside the brain, as well as methods of promoting weight loss and treating obesity using such compounds are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018351936A1
Jurisdiction
AU
Classification
—
Expires
2020-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Instituto de Medicina Molecular Joao Lobo Antunes
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.